UNSPSC 51291509: Fenmetozole

This classification denotes an antidepressant agent with the molecular formula C10H10Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C15WFN6GMO, chemically known as 1h-imidazole, 2-((3,4-dichlorophenoxy)methyl)-4,5-dihydro- but generally known as fenmetozole, which bears US NIH Compound Identifier 32049. European Medicines Agency schedules Fenmetozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07571MIG. The term FENMETOZOLE is an International Non-Proprietary Name.

UNSPSC 51291509 Fenmetozole, a Commodity code, does not align with the state and local procurement activity posted under this classification. The recent opportunities tagged to this code solicit naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are fenmetozole or fungicide active ingredients. The code shows little relevant recent activity; the mismatch suggests either a data classification error in the state and local procurement system or that fenmetozole itself is not currently solicited through state and local channels at volumes sufficient to generate public notices.

The three visible opportunities span different issuing bodies and procurement stages. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for a future therapeutic pharmacy initiative. The Minnesota Department of Administration, through the Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. All three solicitations involve pharmaceutical or health-related products but operate outside the scope of fenmetozole procurement. Business developers should verify the correct UNSPSC classification before pursuing activity under this code.